title: Pathophysiological roles of FGF signaling in the heart.
abstract: Cardiac remodeling progresses to heart failure, which represents a major cause of morbidity and mortality. Cardiomyokines, cardiac secreted proteins, may play roles in cardiac remodeling. Fibroblast growth factors (FGFs) are secreted proteins with diverse functions, mainly in development and metabolism. However, some FGFs play pathophysiological roles in cardiac remodeling as cardiomyokines. FGF2 promotes cardiac hypertrophy and fibrosis by activating MAPK signaling through the activation of FGF receptor (FGFR) 1c. In contrast, FGF16 may prevent these by competing with FGF2 for the binding site of FGFR1c. FGF21 prevents cardiac hypertrophy by activating MAPK signaling through the activation of FGFR1c with β-Klotho as a co-receptor. In contrast, FGF23 induces cardiac hypertrophy by activating calcineurin/NFAT signaling without αKlotho. These FGFs play crucial roles in cardiac remodeling via distinct action mechanisms. These findings provide new insights into the pathophysiological roles of FGFs in the heart and may provide potential therapeutic strategies for heart failure.
authors.affiliation: Department of Genetic Biochemistry, Kyoto University Graduate School of Pharmaceutical Sciences Kyoto, Japan.
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Itoh
authors.forename: Hiroya
authors.initials: H
authors.lastname: Ohta
keywords: FGF; cardiomyokine; fibrosis; heart; heart failure; hypertrophy
references.citation: J Biol Chem. 2006 Jun 9;281(23):15694-700
references.pmid: 16597617
references.citation: Mol Endocrinol. 2010 Oct;24(10):2050-64
references.pmid: 20667984
references.citation: Mol Cell Pharmacol. 2010;2(4):143-154
references.pmid: 21274419
references.citation: Dev Dyn. 2008 Oct;237(10):2947-54
references.pmid: 18816849
references.citation: Am J Physiol Cell Physiol. 2008 May;294(5):C1242-9
references.pmid: 18337564
references.citation: Trends Mol Med. 2011 Apr;17(4):207-14
references.pmid: 21277256
references.citation: J Cell Physiol. 2008 Apr;215(1):1-7
references.pmid: 18064602
references.citation: Circulation. 2009 May 19;119(19):2545-52
references.pmid: 19414634
references.citation: Am J Physiol Endocrinol Metab. 2013 Apr 15;304(8):E863-73
references.pmid: 23443925
references.citation: Am J Pathol. 2007 Nov;171(5):1431-40
references.pmid: 17872976
references.citation: Genes Cells. 2013 Jul;18(7):544-53
references.pmid: 23600527
references.citation: J Clin Invest. 2001 Dec;108(12):1843-51
references.pmid: 11748268
references.citation: Nat Commun. 2013;4:2019
references.pmid: 23771152
references.citation: J Biochem. 2011 Feb;149(2):121-30
references.pmid: 20940169
references.citation: Nat Rev Mol Cell Biol. 2013 Mar;14(3):166-80
references.pmid: 23403721
references.citation: Cell Tissue Res. 2010 Oct;342(1):1-11
references.pmid: 20730630
references.citation: Curr Opin Nephrol Hypertens. 2012 Jul;21(4):369-75
references.pmid: 22531163
references.citation: J Biol Chem. 1994 Jan 14;269(2):1110-9
references.pmid: 7507104
references.citation: Mol Endocrinol. 2008 Apr;22(4):1006-14
references.pmid: 18187602
references.citation: Annu Rev Physiol. 2013;75:503-33
references.pmid: 23398153
references.citation: J Clin Invest. 1996 Jan 15;97(2):281-91
references.pmid: 8567946
references.citation: J Cell Physiol. 2005 Mar;202(3):891-9
references.pmid: 15389635
references.citation: Cardiovasc Res. 2004 Aug 15;63(3):423-32
references.pmid: 15276467
references.citation: Cell Mol Life Sci. 2012 Apr;69(7):1067-76
references.pmid: 21947499
references.citation: J Clin Invest. 2011 Nov;121(11):4393-408
references.pmid: 21985788
references.citation: Biochim Biophys Acta. 2011 Jul;1812(7):791-5
references.pmid: 21504790
references.citation: J Clin Invest. 2012 Jul;122(7):2543-53
references.pmid: 22728934
references.citation: Curr Opin Biotechnol. 2010 Oct;21(5):621-6
references.pmid: 20637599